ATE212552T1 - Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten - Google Patents
Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheitenInfo
- Publication number
- ATE212552T1 ATE212552T1 AT99917572T AT99917572T ATE212552T1 AT E212552 T1 ATE212552 T1 AT E212552T1 AT 99917572 T AT99917572 T AT 99917572T AT 99917572 T AT99917572 T AT 99917572T AT E212552 T1 ATE212552 T1 AT E212552T1
- Authority
- AT
- Austria
- Prior art keywords
- tnf
- signal transduction
- transduction pathway
- treatment
- alpha induced
- Prior art date
Links
- 230000004130 lipolysis Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 230000019491 signal transduction Effects 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000021588 free fatty acids Nutrition 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8215298P | 1998-04-17 | 1998-04-17 | |
| US8274198P | 1998-04-23 | 1998-04-23 | |
| PCT/US1999/008364 WO1999053927A1 (en) | 1998-04-17 | 1999-04-16 | Methods for treating and preventing insulin resistance and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE212552T1 true ATE212552T1 (de) | 2002-02-15 |
Family
ID=26767120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99917572T ATE212552T1 (de) | 1998-04-17 | 1999-04-16 | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1071429B1 (de) |
| AT (1) | ATE212552T1 (de) |
| DE (1) | DE69900847T2 (de) |
| WO (1) | WO1999053927A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072888A1 (en) | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
| US7119114B1 (en) | 1999-08-19 | 2006-10-10 | Signal Pharmaceuticals, Llc | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
| SE0000718D0 (sv) * | 2000-03-03 | 2000-03-03 | Pharmacia & Upjohn Ab | New use |
| CN1440383A (zh) * | 2000-04-28 | 2003-09-03 | 三共株式会社 | PPARγ调制剂 |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| US6987184B2 (en) | 2001-02-15 | 2006-01-17 | Signal Pharmaceuticals, Llc | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
| WO2002085396A1 (en) * | 2001-04-24 | 2002-10-31 | President And Fellows Of Harvard College | Inhibition of jun kinase |
| US7018999B2 (en) | 2001-05-16 | 2006-03-28 | Cephalon, Inc. | Methods for the treatment and prevention of pain |
| JP2005533748A (ja) | 2002-03-08 | 2005-11-10 | シグナル ファーマシューティカルズ，インコーポレイテッド | 増殖性障害および癌を治療、予防、または管理するための併用療法 |
| EP1539931A4 (de) * | 2002-06-27 | 2006-08-23 | Univ Queensland | Differenzierungsmodulierende agentien und verwendungen dafür |
| JP4705782B2 (ja) * | 2002-10-23 | 2011-06-22 | スキャンポ・アーゲー | 肥満の処置のためのプロスタグランジン化合物 |
| EP3235384B1 (de) | 2003-11-25 | 2019-08-28 | Virginia Tech Intellectual Properties, Inc. | Zusammensetzung zum verzehr für tiere |
| KR101660989B1 (ko) | 2007-10-01 | 2016-09-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절 |
| CA2839437A1 (en) | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
-
1999
- 1999-04-16 AT AT99917572T patent/ATE212552T1/de not_active IP Right Cessation
- 1999-04-16 EP EP99917572A patent/EP1071429B1/de not_active Expired - Lifetime
- 1999-04-16 WO PCT/US1999/008364 patent/WO1999053927A1/en not_active Ceased
- 1999-04-16 DE DE69900847T patent/DE69900847T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999053927A1 (en) | 1999-10-28 |
| DE69900847T2 (de) | 2002-09-12 |
| EP1071429A1 (de) | 2001-01-31 |
| EP1071429B1 (de) | 2002-01-30 |
| DE69900847D1 (de) | 2002-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE212552T1 (de) | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| ATE323482T1 (de) | Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
| ATE451930T1 (de) | Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis | |
| DE60117607D1 (de) | Verfahren zur Behandlung von mit p38-Kinase assoziierten Leiden und Pyrrolotriazin-Verbindungen als Kinaseinhibitoren. | |
| DE60113815D1 (de) | Behandlung cytokin-vermittelter krankheiten mit tec familie protein tyrosin kinase inhibitoren | |
| ATE362363T1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
| ATE292462T1 (de) | Behandlung von asthma anhand von mek-inhibitoren | |
| Pan et al. | Interplay of angiotensin II and angiotensin (1–7) in the regulation of matrix metalloproteinases of human cardiocytes | |
| ATE395083T1 (de) | Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität | |
| DE69833971D1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| ATE173630T1 (de) | Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren | |
| ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
| DE69231672D1 (de) | Verfahren zur inhibierung von aldh-i zur behandlung von alkoholabhaengigkeit oder-missbrauch | |
| NO20034549L (no) | Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV | |
| ATE309795T1 (de) | Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes | |
| WO2002039994A3 (en) | Methods for the treatment and prevention of urinary stone disease | |
| ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
| DE60231896D1 (de) | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| ATE486612T1 (de) | Verfahren zur behandlung von diabetes typ 2 | |
| ATE203162T1 (de) | Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |